PUT/VERTEX PHARMACEUTICALS/300/0.1/17.01.25 | Market Closed - BOERSE MUENCHEN 11:56:42 28/06/2024 pm IST | ||
| 0.161 EUR | +20.15% |
|
| Current month | -46.51% | ||
| 1 month | -49.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.161 | +20.15% |
| 27/24/27 | 0.134 | -12.42% |
| 26/24/26 | 0.153 | +28.57% |
| 25/24/25 | 0.119 | -12.50% |
| 24/24/24 | 0.136 | +0.74% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 11:56 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GZ7P47 |
| ISIN | DE000GZ7P478 |
| Date issued | 25/01/2023 |
| Strike | 300 $ |
| Maturity | 17/01/2025 (203 Days) |
| Parity | 10 : 1 |
| Emission price | 3.25 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.75 € |
|---|---|
| Lowest since issue | 0.101 € |
| Spread | 0.3 € |
| Spread % | 73.17% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
